Skip to main content
Erschienen in: Supportive Care in Cancer 12/2009

01.12.2009 | Original Article

Effect of intravenous administration of paracetamol on morphine consumption in cancer pain control

verfasst von: Buket Tasmacioglu, Isik Aydinli, Kader Keskinbora, Ali Ferit Pekel, Tamer Salihoglu, Abdullah Sonsuz

Erschienen in: Supportive Care in Cancer | Ausgabe 12/2009

Einloggen, um Zugang zu erhalten

Abstract

Objective

The present study aimed to examine the effectiveness of intravenous administration of paracetamol added to morphine in the control of cancer pain and its possible contribution as reduction of opioid consumption and opioid-related side effects.

Materials and methods

A total of 43 patients with chronic cancer pain without neuropathic origin aged between 18 and 76 years and receiving step 2 treatment according to the World Health Organization analgesic ladder were included. Patients were randomized to receive intravenous administration of saline (control) or 1 g of paracetamol on top of morphine. Visual analog scale (VAS), patient rating index (PRI), Eastern Cooperative Oncology Group (ECOG) status, patient satisfaction, and safety were evaluated.

Main results

Both treatments resulted in improved VAS and PRI scores compared to baseline. However, groups did not differ in terms of VAS and PRI scores, morphine consumption, side-effect frequencies, laboratory values, ECOG status, and patient satisfaction.

Conclusions

Although safe and there are signals for a true analgesic efficacy, our results failed to confirm any benefits of add-on treatment with intravenous administration of paracetamol. However, the study was underpowered, and future studies in this important area need to be wary of background noise and the risk of a type II error.
Literatur
1.
Zurück zum Zitat Axelsson B, Stellborn P, Ström G (2008) Analgesic effect of paracetamol on cancer related pain in concurrent strong opioid therapy. A prospective clinical study. Acta Oncol 47:891–895CrossRefPubMed Axelsson B, Stellborn P, Ström G (2008) Analgesic effect of paracetamol on cancer related pain in concurrent strong opioid therapy. A prospective clinical study. Acta Oncol 47:891–895CrossRefPubMed
2.
Zurück zum Zitat Blayney MR, Ryan JD, Malins AF (2003) Propofol target-controlled infusions for sedation—a safe technique for the non-anaesthetist? Br Dent J 194:450–452CrossRefPubMed Blayney MR, Ryan JD, Malins AF (2003) Propofol target-controlled infusions for sedation—a safe technique for the non-anaesthetist? Br Dent J 194:450–452CrossRefPubMed
3.
Zurück zum Zitat Botting R, Ayoub SS (2005) COX 3 and the mechanism of action of paracetamol/acetaminophen. Prostaglandins, Leukotrienes and Essential Fatty Acids 72:85–87CrossRef Botting R, Ayoub SS (2005) COX 3 and the mechanism of action of paracetamol/acetaminophen. Prostaglandins, Leukotrienes and Essential Fatty Acids 72:85–87CrossRef
4.
Zurück zum Zitat Botting RM (2000) Mechanism of action of acetaminophen: is there a cyclooxygenase 3? Clin Infect Dis 31(Suppl 5):S202–210CrossRefPubMed Botting RM (2000) Mechanism of action of acetaminophen: is there a cyclooxygenase 3? Clin Infect Dis 31(Suppl 5):S202–210CrossRefPubMed
5.
Zurück zum Zitat Brune K, Zeilhofer HU (2003) Antipyretic analgesics. In: Melzack R, Wall PD (eds) Handbook of pain management. Churchill Livingstone, Edinburg, pp 1139–1153 Brune K, Zeilhofer HU (2003) Antipyretic analgesics. In: Melzack R, Wall PD (eds) Handbook of pain management. Churchill Livingstone, Edinburg, pp 1139–1153
6.
Zurück zum Zitat Cherny N (2003) The management of cancer pain. In: Melzack R, Wall PD (eds) Handbook of pain management. Churchill Livingstone, Edinburg, pp 641–666CrossRef Cherny N (2003) The management of cancer pain. In: Melzack R, Wall PD (eds) Handbook of pain management. Churchill Livingstone, Edinburg, pp 641–666CrossRef
7.
Zurück zum Zitat Delbos A, Boccard E (1995) The morphine sparing effect of propacetamol in orthopedic postoperative pain. J Pain Symptom Manage 10:279–286CrossRefPubMed Delbos A, Boccard E (1995) The morphine sparing effect of propacetamol in orthopedic postoperative pain. J Pain Symptom Manage 10:279–286CrossRefPubMed
8.
Zurück zum Zitat Fitzgibbon DR, Chapman CR (2001) Cancer pain: assessment and diagnosis. In: Loeser JD (ed) Bonica's management of pain, IIIth edn. Lipponcott Williams & Wilkins, Philadelphia, pp 623–658 Fitzgibbon DR, Chapman CR (2001) Cancer pain: assessment and diagnosis. In: Loeser JD (ed) Bonica's management of pain, IIIth edn. Lipponcott Williams & Wilkins, Philadelphia, pp 623–658
9.
10.
11.
12.
Zurück zum Zitat Hernandez-Palazon J, Tortosa JA, Martinez-Lage JF, Perez-Flores D (2001) Intravenous administration of propacetamol reduces morphine consumption after spinal fusion surgery. Anesth Analg 92:1473–1476CrossRefPubMed Hernandez-Palazon J, Tortosa JA, Martinez-Lage JF, Perez-Flores D (2001) Intravenous administration of propacetamol reduces morphine consumption after spinal fusion surgery. Anesth Analg 92:1473–1476CrossRefPubMed
13.
Zurück zum Zitat New South Wales Therapeutic Advisory Group (2005) IV paracetamol-where does it sit in hospital practice? Current Opinion October 1-8. New South Wales Therapeutic Advisory Group (2005) IV paracetamol-where does it sit in hospital practice? Current Opinion October 1-8.
14.
Zurück zum Zitat Peduto VA, Ballabio M, Stefanini S (1998) Efficacy of propacetamol in the treatment of postoperative pain. Morphine-sparing effect in orthopedic surgery. Italian Collaborative Group on Propacetamol. Acta Anaesthesiol Scand 42:293–298CrossRefPubMed Peduto VA, Ballabio M, Stefanini S (1998) Efficacy of propacetamol in the treatment of postoperative pain. Morphine-sparing effect in orthopedic surgery. Italian Collaborative Group on Propacetamol. Acta Anaesthesiol Scand 42:293–298CrossRefPubMed
15.
Zurück zum Zitat Pelissier T, Allou A, Caussade F, Dubray C, Cloarec A, Lavarenne J, Eschalier A (1996) Paracetamol exerts a spinal antinociceptive effect involving an indirect interaction with 5-hydroxytryptamine-3 receptors: in vivo and in vitro evidence. J Pharmacol Exp Ther 278:8–14PubMed Pelissier T, Allou A, Caussade F, Dubray C, Cloarec A, Lavarenne J, Eschalier A (1996) Paracetamol exerts a spinal antinociceptive effect involving an indirect interaction with 5-hydroxytryptamine-3 receptors: in vivo and in vitro evidence. J Pharmacol Exp Ther 278:8–14PubMed
16.
Zurück zum Zitat Pettersson PH, Jakobsson J, Öwall A (2005) Intravenous acetaminophen reduced the use of opioids compared with oral administration after coronary artery bypass grafting. J Cardiothorac Vasc Anesth 19:306–309CrossRefPubMed Pettersson PH, Jakobsson J, Öwall A (2005) Intravenous acetaminophen reduced the use of opioids compared with oral administration after coronary artery bypass grafting. J Cardiothorac Vasc Anesth 19:306–309CrossRefPubMed
17.
Zurück zum Zitat Prescott LF (2000) Therapeutic misadventure with paracetamol: fact or fiction. Am J Ther 7:99–114CrossRefPubMed Prescott LF (2000) Therapeutic misadventure with paracetamol: fact or fiction. Am J Ther 7:99–114CrossRefPubMed
18.
Zurück zum Zitat Rodrigez MJ, Contreras D, Galvez R, Castro A, Camba MA, Busqueta C, Herrera J (2003) Double-blind evaluation of short-term analgesic efficacy of orally administered dexketoprofen trometamol and ketorolac in bone cancer pain. Pain 104:103–110CrossRef Rodrigez MJ, Contreras D, Galvez R, Castro A, Camba MA, Busqueta C, Herrera J (2003) Double-blind evaluation of short-term analgesic efficacy of orally administered dexketoprofen trometamol and ketorolac in bone cancer pain. Pain 104:103–110CrossRef
19.
Zurück zum Zitat Schug SA (2005) Clinical pharmacology of non-opioid and opioid analgesics. In: Justins DM (ed) PAIN 2005-An Updated Review. IASP Press, Seattle, pp 31–38 Schug SA (2005) Clinical pharmacology of non-opioid and opioid analgesics. In: Justins DM (ed) PAIN 2005-An Updated Review. IASP Press, Seattle, pp 31–38
20.
Zurück zum Zitat Sinatra RS, Jahr JS, Reynolds LW, Viscusi ER, Groudine SB, Payen-Champenois C (2005) Efficacy and safety of single and repeated administration of 1 gram intravenous acetaminophen injection (paracetamol) for pain management after major orthopedic surgery. Anesthesiology 102:822–831CrossRefPubMed Sinatra RS, Jahr JS, Reynolds LW, Viscusi ER, Groudine SB, Payen-Champenois C (2005) Efficacy and safety of single and repeated administration of 1 gram intravenous acetaminophen injection (paracetamol) for pain management after major orthopedic surgery. Anesthesiology 102:822–831CrossRefPubMed
21.
Zurück zum Zitat Stockler M, Vardy J, Pillai A, Warr D (2004) Acetaminophen (paracetamol) improves pain and well-being in people with advanced cancer already receiving a strong opioid regimen: A randomized, double-blind, placebo-controlled cross-over trial. J Clin Oncol 22:3389–3394CrossRefPubMed Stockler M, Vardy J, Pillai A, Warr D (2004) Acetaminophen (paracetamol) improves pain and well-being in people with advanced cancer already receiving a strong opioid regimen: A randomized, double-blind, placebo-controlled cross-over trial. J Clin Oncol 22:3389–3394CrossRefPubMed
22.
Zurück zum Zitat World Health Organization (1998) Cancer pain relief and palliative care in children. WHO, Geneva World Health Organization (1998) Cancer pain relief and palliative care in children. WHO, Geneva
23.
Zurück zum Zitat World Health Organization (1996) Cancer pain relief, with a guide to opioid availability, 2nd edn. World Health Organization, Geneva World Health Organization (1996) Cancer pain relief, with a guide to opioid availability, 2nd edn. World Health Organization, Geneva
24.
Zurück zum Zitat Zernikow B, Smale H, Michel E, Hasan C, Jorch N, Andler C (2006) Paediatric cancer pain management using the WHO analgesic ladder—results of a prospective analysis from 2265 treatment days during a guality improvement study. Eur J Pain 10:587–595CrossRefPubMed Zernikow B, Smale H, Michel E, Hasan C, Jorch N, Andler C (2006) Paediatric cancer pain management using the WHO analgesic ladder—results of a prospective analysis from 2265 treatment days during a guality improvement study. Eur J Pain 10:587–595CrossRefPubMed
25.
Zurück zum Zitat Dworkin RH, Turk DC, Farrar JT, Haythornthwaite JA, Jensen MP, Katz NP, Kerns RD et al (2005) Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain 113:9–19CrossRefPubMed Dworkin RH, Turk DC, Farrar JT, Haythornthwaite JA, Jensen MP, Katz NP, Kerns RD et al (2005) Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain 113:9–19CrossRefPubMed
Metadaten
Titel
Effect of intravenous administration of paracetamol on morphine consumption in cancer pain control
verfasst von
Buket Tasmacioglu
Isik Aydinli
Kader Keskinbora
Ali Ferit Pekel
Tamer Salihoglu
Abdullah Sonsuz
Publikationsdatum
01.12.2009
Verlag
Springer-Verlag
Erschienen in
Supportive Care in Cancer / Ausgabe 12/2009
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-009-0612-8

Weitere Artikel der Ausgabe 12/2009

Supportive Care in Cancer 12/2009 Zur Ausgabe

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

28.05.2024 NSCLC Nachrichten

Eine perioperative Therapie mit Nivolumab reduziert das Risiko für Rezidive und Todesfälle bei operablem NSCLC im Vergleich zu einer alleinigen neoadjuvanten Chemotherapie um über 40%. Darauf deuten die Resultate der Phase-3-Studie CheckMate 77T.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.